Pathway analysis has been widely used to detect pathways and functions associated with complex disease phenotypes. The proliferation of this approach is due to better interpretability of its results and its higher statistical power compared with the gene-level statistics. A plethora of pathway analysis methods that utilize multi-omics setup, rather than just transcriptomics or proteomics, have recently been developed to discover novel pathways and biomarkers. Since multi-omics gives multiple views into the same problem, different approaches are employed in aggregating these views into a comprehensive biological context. As a result, a variety of novel hypotheses regarding disease ideation and treatment targets can be formulated. In this article, we review 32 such pathway analysis methods developed for multi-omics and multi-cohort data. We discuss their availability and implementation, assumptions, supported omics types and databases, pathway analysis techniques and integration strategies. A comprehensive assessment of each method’s practicality, and a thorough discussion of the strengths and drawbacks of each technique will be provided. The main objective of this survey is to provide a thorough examination of existing methods to assist potential users and researchers in selecting suitable tools for their data and analysis purposes, while highlighting outstanding challenges in the field that remain to be addressed for future development.
- Award ID(s):
- 2051800
- NSF-PAR ID:
- 10400216
- Date Published:
- Journal Name:
- Biomolecules
- Volume:
- 12
- Issue:
- 10
- ISSN:
- 2218-273X
- Page Range / eLocation ID:
- 1444
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
more » « less
Abstract -
more » « less
Abstract Atopic dermatitis (AD) is a common skin disease in childhood whose diagnosis requires expertise in dermatology. Recent studies have indicated that host genes–microbial interactions in the gut contribute to human diseases including AD. We sought to develop an accurate and automated pipeline for AD diagnosis based on transcriptome and microbiota data. Using these data of 161 subjects including AD patients and healthy controls, we trained a machine learning classifier to predict the risk of AD. We found that the classifier could accurately differentiate subjects with AD and healthy individuals based on the omics data with an average F1-score of 0.84. With this classifier, we also identified a set of 35 genes and 50 microbiota features that are predictive for AD. Among the selected features, we discovered at least three genes and three microorganisms directly or indirectly associated with AD. Although further replications in other cohorts are needed, our findings suggest that these genes and microbiota features may provide novel biological insights and may be developed into useful biomarkers of AD prediction.
-
With rapid progress in high-throughput genotyping and neuroimaging, researches of complex brain disorders, such as Alzheimer’s Disease (AD), have gained significant attention in recent years. Many prediction models have been studied to relate neuroimaging measures to cognitive status over the progressions when these disease develops. Missing data is one of the biggest challenge in accurate cognitive score prediction of subjects in longitudinal neuroimaging studies. To tackle this problem, in this paper we propose a novel formulation to learn an enriched representation for imaging biomarkers that can simultaneously capture both the information conveyed by baseline neuroimaging records and that by progressive variations of varied counts of available follow-up records over time. While the numbers of the brain scans of the participants vary, the learned biomarker representation for every participant is a fixed-length vector, which enable us to use traditional learning models to study AD developments. Our new objective is formulated to maximize the ratio of the summations of a number of L1-norm distances for improved robustness, which, though, is difficult to efficiently solve in general. Thus we derive a new efficient iterative solution algorithm and rigorously prove its convergence. We have performed extensive experiments on the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset. A performance gain has been achieved to predict four different cognitive scores, when we compare the original baseline representations against the learned representations with enrichments. These promising empirical results have demonstrated improved performances of our new method that validate its effectiveness.more » « less
-
Abstract Objective Modern healthcare data reflect massive multi-level and multi-scale information collected over many years. The majority of the existing phenotyping algorithms use case–control definitions of disease. This paper aims to study the time to disease onset and progression and identify the time-varying risk factors that drive them. Materials and Methods We developed an algorithmic approach to phenotyping the incidence of diseases by consolidating data sources from the UK Biobank (UKB), including primary care electronic health records (EHRs). We focused on defining events, event dates, and their censoring time, including relevant terms and existing phenotypes, excluding generic, rare, or semantically distant terms, forward-mapping terminology terms, and expert review. We applied our approach to phenotyping diabetes complications, including a composite cardiovascular disease (CVD) outcome, diabetic kidney disease (DKD), and diabetic retinopathy (DR), in the UKB study. Results We identified 49 049 participants with diabetes. Among them, 1023 had type 1 diabetes (T1D), and 40 193 had type 2 diabetes (T2D). A total of 23 833 diabetes subjects had linked primary care records. There were 3237, 3113, and 4922 patients with CVD, DKD, and DR events, respectively. The risk prediction performance for each outcome was assessed, and our results are consistent with the prediction area under the ROC (receiver operating characteristic) curve (AUC) of standard risk prediction models using cohort studies. Discussion and Conclusion Our publicly available pipeline and platform enable streamlined curation of incidence events, identification of time-varying risk factors underlying disease progression, and the definition of a relevant cohort for time-to-event analyses. These important steps need to be considered simultaneously to study disease progression.more » « less
-
more » « less
Abstract In clinical research and practice, landmark models are commonly used to predict the risk of an adverse future event, using patients' longitudinal biomarker data as predictors. However, these data are often observable only at intermittent visits, making their measurement times irregularly spaced and unsynchronized across different subjects. This poses challenges to conducting dynamic prediction at any post‐baseline time. A simple solution is the last‐value‐carry‐forward method, but this may result in bias for the risk model estimation and prediction. Another option is to jointly model the longitudinal and survival processes with a shared random effects model. However, when dealing with multiple biomarkers, this approach often results in high‐dimensional integrals without a closed‐form solution, and thus the computational burden limits its software development and practical use. In this article, we propose to process the longitudinal data by functional principal component analysis techniques, and then use the processed information as predictors in a class of flexible linear transformation models to predict the distribution of residual time‐to‐event occurrence. The measurement schemes for multiple biomarkers are allowed to be different within subject and across subjects. Dynamic prediction can be performed in a real‐time fashion. The advantages of our proposed method are demonstrated by simulation studies. We apply our approach to the African American Study of Kidney Disease and Hypertension, predicting patients' risk of kidney failure or death by using four important longitudinal biomarkers for renal functions.
- Free Publicly Accessible Full Text
-
Accepted Manuscript1.0
- Journal Article:
- https://doi.org/10.3390/biom12101444
